Joan Lovelette Email & Phone Number

Saint Paul, Mn, Us

Saint Paul, Mn, Us

Greater Minneapolis-St. Paul Area

Notable achievements: exceeded FY 2017 goal by 20% (goal:$400,000/actual: $480,000), on track to exceed FY 2018 goal ($1.3M, current $1.2M.)-Develop and execute ongoing strategies for corporate donors to ensure retention and growth.-Collaborate with National Red Cross on customized solicitation strategies to match the objectives of the Red Cross and interests of the donor.-Prospect development, to ensure a consistent pipeline of donors to meet overall regional goals.-Progression in level of gift amounts, to asks of $10,000+. Corporate contacts include: US Bank, Ecolab, Pentair, Xcel Energy, Centerpoint Energy, Great Clips, Sun Country Airlines

St Paul, Mn

Notable achievements: Met and exceeded all sales quotas, increase in new accounts helped the region to achieve overall collections goals.-This role was one of eight in the nation. My experience and success in the role helped to develop the current job description, expectations, and encouraged the Red Cross to expand this role across the organization.-Focused on new business development, vertical markets, and key accounts.-Developed strategies to recruit, retain, and manage new sponsor organizations. This required extensive working knowledge of the region, as well as the competitive landscape.-Collaborated with and managed individual Account Managers (20) in aforementioned, and overall territory development.

Notable achievements: 106% to goal, ranking #2 in district.-Facilitated district sales strategies to increase market share for asthma, cardiovascular, and pain products.

Notable achievements: gained access to no-access clinics at The University of MN, including Internal Medicine and Women's Clinic. Gained formulary approval for Tekturna and Valturna at The University of MN. Recipient of 17 awards, including #1 Regional Producer for Tekturna.Call points included: Fairview, Allina, Health Partners and VA Systems.Products included: CV, GI, and URO, calling on cardiologists, nephrologists, and endocrinologists.

Responsible for sales growth of products and physician education. Implemented national and regionalstrategies for the promoted products: DiovanHCT, ExforgeHCT, Tekturna, Reclast, Zelnorm. Strongability to work in a team setting. Full understanding of the marketplace, used information to developactionable business plan for the territory to increase sales. Currently sell in a highly competitive market withincreasingly strong relationships. Oversee all aspects of relationship/sales management including account/targets in Northwestern Wisconsin, St. Paul and currently the greater Minneapolis. Implemented an efficient and effective business plan to deliver sales and marketing messages to meet the needs of the customers in a "semi-closed" healthcare environment including Primary Care, IM, CV, Hospitals and Pharmacies. Convert market share from competition through comparative strategic selling and excellent account service. Successfully launched CDM in Minnesota. Initiated and developed several KOL's including internal medicine, physicians, cardiologists, nephrologists, and endocrinologists. Selected as lead sales representative to present a territory analysis with Peter Deane, Director of Global Sales. Responsible for gaining access to no-access clinics at the University of MN including: Internal Medicine, Cardiology, Nephrology, Endocrinology, and Women's Clinic. Top 10% in Sales for Nation for Zelnorm in 2006 Gained support from key physicians for new product formulary coverage for Medica at Drug Formulary Cost Committee meetings.

Detailed and presented the top two cardiovascular products to cardiologists, internal medicine physicians andfamily practitioners. Increased awareness and physician use for Diovan and Lotrel. Represented Starlix forType II diabetes. Participated in obtaining market share for ARB's in Minnesota #1 Territory Sales Representative in District N4

Represented the top two cardiovascular products to a variety of general and specialty physicians.Increased awareness and use for Diovan and Lotrel as well as Starlix for Type II diabetes. Acquired by